Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma
Status:
Unknown status
Trial end date:
2020-05-02
Target enrollment:
Participant gender:
Summary
Currently, there is no standard second line treatment for patients with neuroendocrine
carcinoma. Irinotecan monotherapy or combination regimen has shown promising in previous
study. The study was designed to confirm thet FOLFIRI regimen can be used as a second-line
regimen for patients with advanced or metastatic neuroendocrine carcinoma who have progressed
after first-line chemotherapy with platinum based regimen.